Cognitive Benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu

Yaribeygi, Habib; Maleki, Mina; Sathyapalan, Thozhukat; Rizzo, Manfredi; Sahebkar, Amirhossein

Abstract

Patients with diabetes are at higher risk of cognitive impairment and memory loss than the normal population. Thus, using hypoglycemic agents to improve brain function is important for diabetic patients. Sodium-glucose cotransporters-2 inhibitors (S-GLT2i) are a class of therapeutic agents used in the management of diabetes that has some pharmacologic effects enabling them to fight against the onset and progress of memory deficits. Although the exact mediating pathways are not well understood, emerging evidence suggests that SGLT2 inhibition is associated with improved brain function. This study reviewed the possible mechanisms and provided evidence suggesting SGLT2 inhibitors could ameliorate cognitive deficits.

Citation

Yaribeygi, H., Maleki, M., Sathyapalan, T., Rizzo, M., & Sahebkar, A. (2024). Cognitive Benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu. Current medicinal chemistry, 31(2), 138-151. https://doi.org/10.2174/0929867330666230202163513

• Journal Article Type: Article
• Acceptance Date: Jan 26, 2023
• Online Publication Date: Mar 20, 2023
• Publication Date: Jan 1, 2024
• Deposit Date: Jun 11, 2023
• Publicly Available Date: Mar 21, 2024
• Journal: Current Medicinal Chemistry
• Print ISSN: 0929-8673
• Electronic ISSN: 1875-533X
• Publisher: Bentham Science Publishers
• Peer Reviewed: Peer Reviewed
• Volume: 31
• Issue: 2
• Pages: 138-151
• DOI: https://doi.org/10.2174/0929867330666230202163513
• Keywords: Diabetes mellitus; Sodium-glucose cotransporters-2 inhibitors; Oxidative stress; Apoptosis; Cognition; Memory
• Public URL: https://hull-repository.worktribe.com/output/4311791